PRESS RELEASES
Apposition III Results
STENTYS expands its product offerings
STENTYS Self-Apposing technology supported by breaking new scientific evidence
Increased reimbursement of Self-Expanding drug-eluting stents in Germany now for all indications
STENTYS concludes clinical trial ahead of plan
Outstanding interim results of STENTYS international clinical study APPOSITION III
STENTYS Self-Apposing Stents in “perfect apposition to vessels” after treating patients with heart attacks
STENTYS completes enrollment of APPOSITION III study
Over 1000 patients have benefited from STENTYS Self-Apposing technology
2011 Half-Year results
Revenues for the 1st half of 2011
Prof. Gilles Montalescot joins STENTYS Scientific Advisory Board
STENTYS recruits Country managers for France and Italy
STENTYS joins Stent for Life Initiative
Stenting in STEMI: Does Size Matter?
STENTYS enrolls first 250 patients within the framework of its Apposition III international study
STENTYS expands operations into four additional European countries
Increased reimbursement of STENTYS drug-eluting stent in Germany
STENTYS begins large-scale, “real life” study with its selfapposing stent for treatment of Heart Attacks
50 patients already enrolled
STENTYS appoints Mr Michel Darnaud to its Board of Directors
APPOSITION II clinical trial results
STENTYS self-apposing stent proves superior to conventional treatment of Acute Myocardial Infarction


